Compare · HSDT vs LIVN
HSDT vs LIVN
Side-by-side comparison of Solana Company (HSDT) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HSDT and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.53B, about 43.1x HSDT ($105.1M).
- Over the past year, HSDT is down 69.7% and LIVN is up 51.7% - LIVN leads by 121.4 points.
- LIVN has been more active in the news (7 items in the past 4 weeks vs 2 for HSDT).
- LIVN has more recent analyst coverage (20 ratings vs 3 for HSDT).
- Company
- Solana Company
- LivaNova PLC
- Price
- $1.79+2.87%
- $82.16+1.63%
- Market cap
- $105.1M
- $4.53B
- 1M return
- +3.47%
- +3.46%
- 1Y return
- -69.71%
- +51.67%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 2
- 7
- Recent ratings
- 3
- 20
Solana Company
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest HSDT
- Solana Company to Release Second Quarter 2026 Operating Results on August 14, 2026
- SEC Form 4 filed by CEO and President Chee Choon Wee
- New insider Summer Wisdom Holdings Ltd claimed ownership of 6,830,402 shares (SEC Form 3)
- Large owner Summer Wisdom Holdings Ltd disposed of 1,453,277 shares (SEC Form 4)
- Solana Company Partners with Alatau City to Advance Digital Asset Infrastructure and Blockchain Adoption in Central Asia
- Solana Company Board Unanimously Rejects Unsolicited Forward Industries Proposal
- Director Jiang Cosmo Yi exercised 1,005,040 shares at a strike of $0.00 and covered exercise/tax liability with 610 shares (SEC Form 4)
- SEC Form 4 filed by Director Jiang Cosmo Yi
- Solana Company filed SEC Form 8-K: Entry into a Material Definitive Agreement
- SEC Form 424B5 filed by Solana Company
Latest LIVN
- Chief Innovation Officer Tezel Ahmet exercised 12,692 units of Ordinary Shares at a strike of $52.68, returned $668,740 worth of Ordinary Shares to the company (8,589 units at $77.86), covered exercise/tax liability with 1,428 units of Ordinary Shares and sold $207,942 worth of Ordinary Shares (2,675 units at $77.74) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by LivaNova PLC
- SEC Form IRANNOTICE filed by LivaNova PLC
- SEC Form 10-Q filed by LivaNova PLC
- SEC Form 3 filed by new insider Folli Stefano
- LivaNova PLC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
- LivaNova to Announce Second-Quarter 2026 Results
- Director Wilver Peter M covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 53% to 10,294 units (SEC Form 4)
- Chief Innovation Officer Tezel Ahmet converted options into 2,965 units of Ordinary Shares and covered exercise/tax liability with 1,032 units of Ordinary Shares, increasing direct ownership by 46% to 6,090 units (SEC Form 4)